Inanovate develops a longitudinal assay screening technology for the detection and measurement of multiple proteins.
Inanovate develops a longitudinal assay screening technology for the detection and measurement of multiple proteins. It offers to test and benchmark Bio-ID that consists of a compact bench-top analyzer and disposable test cartridges for precisely measuring the concentration of multiple disease-related biological molecules from patient blood samples.The company was founded in 2006 and is headquartered in Sioux Falls, South Dakota.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 21, 2020 | Grant | $255.85K | 1 |
National Science Foundation
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Science Foundation
|
Yes | Grant |